Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Disease × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioblastoma 1 Estrogen Receptor Positive Breast Cancer 1 Disease 1 Breast Neoplasms 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1

Interventions

Dexamethasone 5 Magnetic Resonance Spectroscopy 4 Cyclophosphamide 4 Blood Specimen Collection 4 Surveys and Questionnaires 3 Prednisone 3 Melphalan 3 Lenalidomide 3 Biopsy, Fine-Needle 3 fluciclovine F-18 2 carfilzomib 2 Positron-Emission Tomography 2 Mammography 2 Injections 2 Immunohistochemistry 2 Gemcitabine 2 Cytarabine 2 weifuchun 1 vistusertib 1 venetoclax 1 ricolinostat 1 pomalidomide 1 phosphoribosylformylglycinamidine synthetase 1 pembrolizumab 1 ofatumumab 1 obinutuzumab 1 irinotecan sucrosofate 1 ibrutinib 1 gossypol acetic acid 1 glycidol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed

Disease, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡